Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects
NCT ID: NCT06379958
Last Updated: 2024-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
48 participants
INTERVENTIONAL
2024-04-08
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Drug-Drug Interaction Between Rifampin and Fluvastatin
NCT04029584
The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
NCT05845567
Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
NCT04606537
Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction
NCT03048110
Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food Effect
NCT03116893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1: Itraconazole 200mg
leramistat 40mg
Oral capsule
Itraconazole 200 mg
Oral capsule
Part 2: Phenytoin 100mg
leramistat 40mg
Oral capsule
Phenytoin 100 Mg Oral Capsule
Oral capsule
Part 3: Simvastatin 40mg
leramistat 40mg
Oral capsule
Simvastatin 40mg
Oral capsule
Part 4: Upadacitinib 15 mg
leramistat 40mg
Oral capsule
Upadacitinib 15 MG
Oral Capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
leramistat 40mg
Oral capsule
Itraconazole 200 mg
Oral capsule
Phenytoin 100 Mg Oral Capsule
Oral capsule
Simvastatin 40mg
Oral capsule
Upadacitinib 15 MG
Oral Capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Modern Biosciences Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Celerion
Belfast, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Phase 1 Unit
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IST-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.